Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor receptor superfamily member 1B (TNFR2) is a membrane-bound receptor that binds to tumor necrosis factor-alpha (TNF-alpha) with high affinity, mediating crucial signaling pathways involved in cell survival, immune regulation, and tissue regeneration. Unlike TNFR1, which is ubiquitously expressed and primarily drives pro-inflammatory and apoptotic pathways, TNFR2 expression is highly restricted to specific immune cell subsets, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as certain endothelial and central nervous system cells. In the tumor microenvironment, TNFR2 is often aberrantly upregulated, promoting tumor cell proliferation, immune evasion, and drug resistance by enhancing the suppressive activity of Tregs. Consequently, TNFR2 has emerged as a highly promising therapeutic target in oncology and autoimmune diseases. Antagonistic antibodies, such as BI-1808, are being developed to deplete immunosuppressive Tregs and reprogram myeloid cells to enhance anti-tumor immunity, while selective TNFR2 agonists, such as TRB-061, are being investigated to expand Tregs and treat inflammatory conditions like atopic dermatitis and multiple sclerosis.
Drugs targeting TNFR2 act either as antagonists or agonists. Antagonistic antibodies block the binding of TNF-alpha to TNFR2 and engage Fcγ receptors to deplete immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, thereby enhancing anti-tumor immune responses. Conversely, agonistic antibodies selectively activate TNFR2 signaling to expand and enhance the suppressive function of Tregs, which helps to restore immune tolerance in autoimmune and inflammatory diseases.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor receptor superfamily member 1B (TNFR2) (TNFR2).